Adimmune

Executive Summary

Adimmune Corp. is a Taiwan-based biotechnology company specializing in recombinant protein subunit vaccines and diagnostic kits for infectious diseases. Founded in 2020, the company leverages a proprietary adjuvant platform to enhance immunogenicity and enable scalable manufacturing. Its pipeline targets COVID-19, influenza, RSV, and other viral pathogens. Adimmune operates at the preclinical stage and has raised $50 million in funding. As a regional player, it aims to address vaccine needs in Asia and beyond. The company's near-term focus is advancing its lead candidates toward clinical trials, with potential catalysts including regulatory submissions, partnerships, and initial clinical data. However, as a private preclinical entity, its valuation and timeline remain uncertain.

Upcoming Catalysts (preview)

• H2 2026IND Filing for Lead COVID-19 Vaccine Candidate60% success
• H1 2027Strategic Partnership or Licensing Deal for Adjuvant Platform50% success
• 2027Initiation of Phase 1 Trial for Influenza Vaccine40% success